The 25 most recent market catalysts affecting $CAPR, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 95
Capricor Therapeutics shares are trading higher after the company announced it will present 24-month Phase 3 HOPE-3 data for its Duchenne muscular dystrophy drug, Deramiocel, following a major BLA amendment submitted to the FDA ahead of its November 22 PDUFA date.
This headline represents a major corporate catalyst for Capricor Therapeutics. The announcement of 24-month Phase 3 data, especially following a BLA amendment, significantly increa…
Sep 17, 2026
Corporate Catalyst
Neutral
Impact 85
Capricor Therapeutics Announces 24-Month HOPE-3 Data On Deramiocel In Duchenne Muscular Dystrophy To Be Presented At World Muscle Society Congress September 29 To October 3
The upcoming presentation of 24-month HOPE-3 data for deramiocel is a critical event for Capricor Therapeutics (CAPR). Positive data, particularly regarding efficacy and safety ove…
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 65
B. Riley Securities Upgrades Capricor Therapeutics to Buy, Raises Price Target to $21
B. Riley Securities analyst Madison El-Saadi upgraded Capricor Therapeutics (CAPR) from Neutral to Buy and raised the price target from $5 to $21. This substantial increase in pric…
Sep 1, 2026
Corporate Catalyst
Bullish
Impact 75
Piper Sandler Upgrades Capricor Therapeutics to Overweight, Raises Price Target to $25
Piper Sandler analyst Edward Tenthoff upgraded Capricor Therapeutics (CAPR) from Neutral to Overweight and dramatically increased the price target from $2 to $25. This is a signifi…
Aug 24, 2026
Corporate Catalyst
Bullish
Impact 75
Why Is Capricor Therapeutics Stock Trading Higher on Monday?
The FDA extended the PDUFA target action date for Capricor Therapeutics' deramiocel, a Duchenne muscular dystrophy treatment, to November 22. This extension is a result of Capricor…
Aug 24, 2026
Corporate Catalyst
Neutral
Impact 75
Capricor Therapeutics Says FDA Extends PDUFA Target Action Date For Its BLA For Deramiocel, Investigational Cell Therapy For Duchenne Muscular Dystrophy, From August 22 To November 22
Capricor Therapeutics received a three-month extension for the FDA's review of its Biologics License Application (BLA) for Deramiocel, an investigational Duchenne muscular dystroph…
Aug 21, 2026
Corporate Catalyst
Neutral
Impact 75
Kaos Capital Plans To Nominate Two Independent Directors On Capricor Therapeutics' Board; To Seek Board-Led M&A, Strategic Alternatives Committee
Kaos Capital, an activist shareholder, is publicly announcing its intent to nominate two independent directors to Capricor Therapeutics' board and to push for a Board-led M&A and S…
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 85
Capricor Therapeutics Remains Optimistic about Deramiocel FDA Approval
Capricor Therapeutics provided an update on its Biologics License Application (BLA) for Deramiocel, indicating active engagement with the FDA and addressing a Form 483 observation.…
Aug 14, 2026
Corporate Catalyst
Neutral
Impact 65
This Capricor Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
The filing reports multiple analyst upgrades across various sectors. The most notable is Capricor Therapeutics (CAPR), which saw its rating jump from Neutral to Overweight and its …
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 85
Capricor Therapeutics shares are trading higher after the company reported Q2 financial results. Cantor Fitzgerald upgraded the stock from Neutral to Overweight and raised its price target from $3.5 to $28.
The headline indicates a strong positive catalyst for Capricor Therapeutics (CAPR). The combination of better-than-expected Q2 financial results and a significant upgrade from Cant…
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 75
12 Health Care Stocks Moving In Friday's Pre-Market Session
The filing highlights pre-market trading activity for 12 healthcare stocks, with several experiencing significant price swings. The primary catalyst for many of these movements, pa…
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 75
Cantor Fitzgerald Upgrades Capricor Therapeutics to Overweight, Raises Price Target to $28
Cantor Fitzgerald analyst Kristen Kluska upgraded Capricor Therapeutics (CAPR) from Neutral to Overweight and raised the price target from $3.50 to $28. This is a significant posit…
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 85
Capricor Therapeutics (CAPR) Shares Soar Over 67% After Hours: Here's Why
Capricor Therapeutics experienced a massive after-hours surge of over 67% despite reporting a Q2 loss of $0.70 per share, missing analyst estimates, and no revenue. The primary cat…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 92
Capricor Therapeutics Q2 EPS $(0.70) Misses $(0.58) Estimate
Capricor Therapeutics (CAPR) announced Q2 earnings per share of $(0.70), missing analyst estimates of $(0.58) by a substantial 20.69%. This is a critical negative catalyst for the …
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 75
Piper Sandler Downgrades Capricor Therapeutics to Neutral, Lowers Price Target to $2
Piper Sandler's downgrade of Capricor Therapeutics from Overweight to Neutral, coupled with a dramatic price target cut from $58 to $2, signals a severe re-evaluation of the compan…
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 95
Capricor Stock Tumbles After FDA Panel Rejects Evidence for Duchenne Cell Therapy
The FDA Advisory Committee's 9-3 vote against Capricor Therapeutics' Deramiocel for Duchenne muscular dystrophy is a major setback for the company. The panel's concerns about insuf…
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 75
Cantor Fitzgerald Downgrades Capricor Therapeutics to Neutral, Lowers Price Target to $3.5
Cantor Fitzgerald's downgrade of Capricor Therapeutics from Overweight to Neutral, coupled with a dramatic price target reduction from $62 to $3.5, indicates a significant loss of …
Jul 29, 2026
Corporate Catalyst
Neutral
Impact 95
'FDA panel votes against Capricor's Duchenne heart disease therapy'- Reuters
The filing reports that an FDA panel voted against Capricor's Duchenne heart disease therapy. This is a critical event for Capricor, as the approval of this therapy was a major cat…
Jul 27, 2026
Corporate Catalyst
Bearish
Impact 95
QUICK SPARK: Capricor Stock Dives — 'Complete Fraud' Says Pharma Bro Martin Shkreli (UPDATED)
Capricor Therapeutics is facing a perfect storm of negative catalysts. Martin Shkreli's high-profile fraud allegations, though unproven, have added significant reputational risk. M…
Jul 27, 2026
Corporate Catalyst
Bearish
Impact 95
Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data
Capricor Therapeutics experienced a sharp decline in its stock price following the release of an FDA briefing document that raised significant concerns about the efficacy of its in…
Jul 27, 2026
Corporate Catalyst
Neutral
Impact 75
Capricor Says FDA Briefing Relies On Obsolete Analysis Plan Ahead Of Deramiocel Advisory Committee Meeting For Duchenne Muscular Dystrophy BLA
Capricor Therapeutics is publicly disputing the FDA's briefing materials for the upcoming advisory committee meeting concerning their Duchenne muscular dystrophy drug, Deramiocel. …
Jul 27, 2026
Corporate Catalyst
Bearish
Impact 95
Capricor Therapeutics Stock Plunges After FDA Releases Briefing Documents
Capricor Therapeutics (CAPR) experienced a massive stock drop exceeding 60% after the FDA released briefing documents for its Duchenne cell therapy, deramiocel. The core issue is t…
Jul 27, 2026
Corporate Catalyst
Bearish
Impact 95
Capricor Therapeutics shares are trading lower after the FDA said the data for the company's Duchenne Cell Therapy does not provide substantial evidence of effectiveness.
This headline represents a major corporate catalyst for Capricor Therapeutics (CAPR). The FDA's statement that the Duchenne cell therapy data 'does not provide substantial evidence…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.